Recent advance in infant nutrition: Human milk oligosaccharides

Breast feeding and human milk are the standards for infant feeding and nutrition. Human milk oligosaccharides (HMOs) are the third most abundant solid component in human milk. To date, more than 200 structural different HMOs have been identified and some can be synthesized by the food industry. HMOs...

Full description

Saved in:
Bibliographic Details
Main Authors: Yu-Jyun Cheng (Author), Chun-Yan Yeung (Author)
Format: Book
Published: Elsevier, 2021-07-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_1b6a1cb6d4d8415195e63a0eb9022f0d
042 |a dc 
100 1 0 |a Yu-Jyun Cheng  |e author 
700 1 0 |a Chun-Yan Yeung  |e author 
245 0 0 |a Recent advance in infant nutrition: Human milk oligosaccharides 
260 |b Elsevier,   |c 2021-07-01T00:00:00Z. 
500 |a 1875-9572 
500 |a 10.1016/j.pedneo.2020.12.013 
520 |a Breast feeding and human milk are the standards for infant feeding and nutrition. Human milk oligosaccharides (HMOs) are the third most abundant solid component in human milk. To date, more than 200 structural different HMOs have been identified and some can be synthesized by the food industry. HMOs are one of the major differences between human milk and formula milk, and current evidence demonstrates their various beneficial effects toward infants' health: acting as anti-adhesive antimicrobials, immune modulators, and intestinal cell response modulators, as well as providing prebiotics effect and neurodevelopment and cognition effects. HMOs compositions vary among mothers, influenced by the stage of lactation, duration of pregnancy and maternal genetic factors. However, there are still some unknown factors affecting the compositions of HMOs and requiring further research for clarification. A combination of preclinical and clinical cohort studies may help to identify whether an individual HMO contributes to disease protection. In recent years, 2'-fucosyllactose (2'-FL) and lacto-N-neotetraose (LNnT) have been approved as food ingredients by official authorities. Infant formulae supplemented with these HMOs are well-tolerated. However, more prospective clinical studies are warranted to elucidate HMOs' significance in infant nutrition. Breast milk feeding remains the best option for infants nutrition and development. Whenever breast milk is not adequate or unavailable, infant formula supplemented with HMOs might be considered as an alternative. 
546 |a EN 
690 |a breast milk 
690 |a human milk oligosaccharides 
690 |a immune modulators 
690 |a infant formula 
690 |a infant nutrition 
690 |a Pediatrics 
690 |a RJ1-570 
655 7 |a article  |2 local 
786 0 |n Pediatrics and Neonatology, Vol 62, Iss 4, Pp 347-353 (2021) 
787 0 |n http://www.sciencedirect.com/science/article/pii/S187595722100053X 
787 0 |n https://doaj.org/toc/1875-9572 
856 4 1 |u https://doaj.org/article/1b6a1cb6d4d8415195e63a0eb9022f0d  |z Connect to this object online.